RESEARCH ARTICLE Joint

pain severity predict discontinuation of aromat 1, R Third-generation aromatase inhibitors (AIs) are commonly American Society of Clinical Oncology guidelines recom-Chim et al. BMC Cancer 2013, 13:401 http://www.biomedcentral.com/1471-2407/13/401mortality in breast cancer patients [6]. In the emergingMedicine at the University of Pennsylvania, Philadelphia, PA 19104, USA Full list of author information is available at the end of the articleprescribed as standard adjuvant therapy for postmeno-pausal breast cancer survivors with hormone-receptor positive disease and are associated with improved disease-free survival compared with the previous standard of tam-oxifen therapy [1-4]. The recommended duration of initial adjuvant endocrine therapy is five years though some mend incorporating an AI either as primary, sequential (following 2–3 years of tamoxifen), or extended therapy (following 5 years of tamoxifen) [5]. Despite the survival benefits of AIs, many women demonstrate some degree of non-adherence with their use. Non-adherence, a term which comprises both non-compliance with dosing, timing, and instruction of medi-cation and non-persistence, or early discontinuation of medication, represents an emergent area to intervene for treatment benefit. Indeed, non-adherence of adjuvant endocrine therapy has been associated with increase